219 related articles for article (PubMed ID: 17276949)
41. Pathological and molecular features of adrenocortical carcinoma: an update.
Volante M; Buttigliero C; Greco E; Berruti A; Papotti M
J Clin Pathol; 2008 Jul; 61(7):787-93. PubMed ID: 18430754
[TBL] [Abstract][Full Text] [Related]
42. Validation of the prognostic role of the "Helsinki Score" in 225 cases of adrenocortical carcinoma.
Duregon E; Cappellesso R; Maffeis V; Zaggia B; Ventura L; Berruti A; Terzolo M; Fassina A; Volante M; Papotti M
Hum Pathol; 2017 Apr; 62():1-7. PubMed ID: 27916625
[TBL] [Abstract][Full Text] [Related]
43. [Adrenocortical tumors. I. Prognostic evaluation of a series of 17 cases using the Weiss criteria].
Wagner M; Walter PR; Ghnassia JP; Gasser B
Ann Pathol; 1993; 13(5):306-11. PubMed ID: 8311856
[TBL] [Abstract][Full Text] [Related]
44. Myxoid variant of adrenocortical carcinoma: report of a unique case.
Karim RZ; Wills EJ; McCarthy SW; Scolyer RA
Pathol Int; 2006 Feb; 56(2):89-94. PubMed ID: 16445821
[TBL] [Abstract][Full Text] [Related]
45. Immunohistochemical evaluation of metallothionein, Mcm-2 and Ki-67 antigen expression in tumors of the adrenal cortex.
Szajerka A; Dziegiel P; Szajerka T; Zabel M; Winowski J; Grzebieniak Z
Anticancer Res; 2008; 28(5B):2959-65. PubMed ID: 19031940
[TBL] [Abstract][Full Text] [Related]
46. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization.
Stojadinovic A; Ghossein RA; Hoos A; Nissan A; Marshall D; Dudas M; Cordon-Cardo C; Jaques DP; Brennan MF
J Clin Oncol; 2002 Feb; 20(4):941-50. PubMed ID: 11844815
[TBL] [Abstract][Full Text] [Related]
47. [Clinical assessment of histological diagnostic systems for adrenocortical tumors].
Bokhyan VY; Pavlovskaya AI; Gubina GI; Stilidi IS
Arkh Patol; 2015; 77(3):17-22. PubMed ID: 26226777
[TBL] [Abstract][Full Text] [Related]
48. [Malignant adrenocortical tumors. Apropos of 9 cases].
Benchekroun A; Benslimane L; Iken A; Chefchaouni MC; Faik M; Marzouk A
Ann Urol (Paris); 1996; 30(1):33-7. PubMed ID: 8712758
[TBL] [Abstract][Full Text] [Related]
49. Adrenocortical carcinoma: review of the pathologic features, production of adrenal steroids, and molecular pathogenesis.
Nakamura Y; Yamazaki Y; Felizola SJ; Ise K; Morimoto R; Satoh F; Arai Y; Sasano H
Endocrinol Metab Clin North Am; 2015 Jun; 44(2):399-410. PubMed ID: 26038208
[TBL] [Abstract][Full Text] [Related]
50. Outcome of adrenocortical tumors in children.
Hanna AM; Pham TH; Askegard-Giesmann JR; Grams JM; Iqbal CW; Stavlo P; Moir CR
J Pediatr Surg; 2008 May; 43(5):843-9. PubMed ID: 18485950
[TBL] [Abstract][Full Text] [Related]
51. Oncocytic adrenocortical carcinomas: a pathological and immunohistochemical study of four cases in comparison with conventional adrenocortical carcinomas.
Song SY; Park S; Kim SR; Suh YL
Pathol Int; 2004 Aug; 54(8):603-10. PubMed ID: 15260851
[TBL] [Abstract][Full Text] [Related]
52. Nestin as a marker in the classification of adrenocortical tumors.
Lachenmayer A; Lichtenauer UD; Cox T; Schott M; Malendowicz LK; Goretzki PE; Cupisti K; Scherbaum WA; Bornstein SR; Willenberg HS
Horm Metab Res; 2009 May; 41(5):397-401. PubMed ID: 19294612
[TBL] [Abstract][Full Text] [Related]
53. Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma.
Fenske W; Völker HU; Adam P; Hahner S; Johanssen S; Wortmann S; Schmidt M; Morcos M; Müller-Hermelink HK; Allolio B; Fassnacht M
Endocr Relat Cancer; 2009 Sep; 16(3):919-28. PubMed ID: 19465749
[TBL] [Abstract][Full Text] [Related]
54. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors.
Arlt W; Biehl M; Taylor AE; Hahner S; Libé R; Hughes BA; Schneider P; Smith DJ; Stiekema H; Krone N; Porfiri E; Opocher G; Bertherat J; Mantero F; Allolio B; Terzolo M; Nightingale P; Shackleton CH; Bertagna X; Fassnacht M; Stewart PM
J Clin Endocrinol Metab; 2011 Dec; 96(12):3775-84. PubMed ID: 21917861
[TBL] [Abstract][Full Text] [Related]
55. Oncocytic adrenocortical tumors: diagnostic algorithm and mitochondrial DNA profile in 27 cases.
Duregon E; Volante M; Cappia S; Cuccurullo A; Bisceglia M; Wong DD; Spagnolo DV; Szpak-Ulczok S; Bollito E; Daffara F; Berruti A; Terzolo M; Papotti M
Am J Surg Pathol; 2011 Dec; 35(12):1882-93. PubMed ID: 21989346
[TBL] [Abstract][Full Text] [Related]
56. [Adrenocortical tumors with neuroendocrine differentiation].
Kazantseva IA; Poliakova GA; Gurevich LG; Morozov IA; Bezuglova TV; Smirnov VB
Arkh Patol; 2002; 64(5):8-13. PubMed ID: 12575533
[TBL] [Abstract][Full Text] [Related]
57. Recent advances in histopathology and immunohistochemistry of adrenocortical carcinoma.
Sasano H; Suzuki T; Moriya T
Endocr Pathol; 2006; 17(4):345-54. PubMed ID: 17525483
[TBL] [Abstract][Full Text] [Related]
58. Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy.
Velázquez-Fernández D; Laurell C; Geli J; Höög A; Odeberg J; Kjellman M; Lundeberg J; Hamberger B; Nilsson P; Bäckdahl M
Surgery; 2005 Dec; 138(6):1087-94. PubMed ID: 16360395
[TBL] [Abstract][Full Text] [Related]
59. [Adrenocortical tumors: mitotic index and nuclear size as criteria for differential diagnosis and prognosis].
Poliakova GA; Kazantseva IA; Kalinin AP; Perov AI; Bokova EV
Arkh Patol; 1999; 61(3):30-4. PubMed ID: 10476345
[TBL] [Abstract][Full Text] [Related]
60. Primary adrenal tumors--a 16-year experience in a single institution.
Białas M; Okoń K; Stachura J
Pol J Pathol; 2008; 59(2):101-6. PubMed ID: 18669176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
